The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers

Abstract Pathogenic germline variants in checkpoint kinase 2 (CHEK2), which plays pivotal roles in DNA damage response and cell cycle regulation, confer an increased breast cancer (BC) risk. Here, we investigated the phenotypic and genomic characteristics of 33 BCs from CHEK2 germline mutation carriers (16 high-risk variants and 17 low-risk p.Ile157Thr variants). CHEK2-associated BCs from patients with high-risk germline variants were largely hormone receptor-positive (87%, 13/15), and 81% (13/16) exhibited loss of heterozygosity (LOH) of the CHEK2 wild-type allele. Conversely, CHEK2-associated BCs from patients with the low-risk p.Ile157Thr variant displayed less-frequent loss of heterozygosity (5/17, 29%) and higher levels of CHEK2 protein expression than those with high-risk germline variants. CHEK2-associated BCs lacked a dominant mutational signature 3, a genomics feature of homologous recombination DNA repair deficiency (HRD). Our findings indicate that CHEK2-associated BCs are generally hormone receptor-positive and lack HRD-related mutational signatures, recapitulating the features of ATM-associated BCs. Specific CHEK2 germline variants may have a distinct impact on tumor biology.

[1]  Rui Bi,et al.  The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. , 2018, Journal of the National Cancer Institute.

[2]  Martin A. M. Reijns,et al.  CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions , 2018, Nature.

[3]  Sitao Wu,et al.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA Oncology.

[4]  J. Reis-Filho,et al.  Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.

[5]  P. Kantoff,et al.  Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.

[6]  Nancy R. Zhang,et al.  BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers , 2017, Nature Communications.

[7]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[8]  I. Papasotiriou,et al.  Current perspectives on CHEK2 mutations in breast cancer , 2017, Breast cancer.

[9]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[10]  A. Whittemore,et al.  Genetic modifiers of CHEK2*1100delC associated breast cancer risk , 2016, Genetics in Medicine.

[11]  Michael Jones,et al.  Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[13]  J. Martens,et al.  Genomic profiling of CHEK2*1100delC-mutated breast carcinomas , 2015, BMC Cancer.

[14]  J. Reis-Filho,et al.  Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. , 2015, Journal of the National Cancer Institute.

[15]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[16]  Lihong Liu,et al.  The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. , 2013, DNA and cell biology.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[18]  Chuan Liu,et al.  The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[19]  Yajie Wang,et al.  The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[20]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Kenneth Offit,et al.  Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. , 2005, Human molecular genetics.